Health |Johnson & Johnson
Johnson & Johnson reports VARIPULSE and OMNYPULSE results for atrial fibrillation
October 22, 2026
Johnson & Johnson reported first real-world VARIPULSE Pro data, including 100% acute procedural success, and 12-month OMNYPULSE results in which 82.5% of patients stayed free of documented atrial arrhythmia.
- PublishedOctober 22, 2026
- IndustryHealth
- LanguageEN
Published by Jnj. Read the original announcement for the full release.
Read the full announcement →